GLP-1 RA therapy reduced mortality from cardiovascular causes (RR: 0.90; 95% CI: 0.83–0.97; P = 0.004) and fatal or non-fatal stroke (RR: 0.85; 95% CI: 0.77–0.94; P = 0.001). This evidence concerns the gene GLP1R and stroke disorder.